162 related articles for article (PubMed ID: 24741582)
1. Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
Zimmermann H; Weiland T; Nourse JP; Gandhi MK; Reinke P; Neuhaus R; Karbasiyan M; Gärtner B; Anagnostopoulos I; Riess H; Trappe RU; Oertel S
J Immunol Res; 2014; 2014():264723. PubMed ID: 24741582
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
3. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
6. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
7. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
[TBL] [Abstract][Full Text] [Related]
8. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
9. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
10. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
11. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Gupta S; Fricker FJ; González-Peralta RP; Slayton WB; Schuler PM; Dharnidharka VR
Pediatr Transplant; 2010 Nov; 14(7):896-902. PubMed ID: 20642490
[TBL] [Abstract][Full Text] [Related]
13. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of post-transplant lymphoproliferative disease with rituximab].
Jiang YJ; Wang X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):852-6. PubMed ID: 24989308
[TBL] [Abstract][Full Text] [Related]
17. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Zimmermann H; Koenecke C; Dreyling MH; Pott C; Dührsen U; Hahn D; Meidenbauer N; Hauser IA; Rummel MJ; Wolf D; Heuser M; Schmidt C; Schlattmann P; Ritgen M; Siebert R; Oschlies I; Anagnostopoulos I; Trappe RU
Leukemia; 2022 Oct; 36(10):2468-2478. PubMed ID: 35974101
[TBL] [Abstract][Full Text] [Related]
18. Treatment of PTLD with rituximab or chemotherapy.
Elstrom RL; Andreadis C; Aqui NA; Ahya VN; Bloom RD; Brozena SC; Olthoff KM; Schuster SJ; Nasta SD; Stadtmauer EA; Tsai DE
Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]